ArticleFrontiers in oncology2025
Monocyte count combined with GTVnx is an independent prognostic factor in non-metastatic nasopharyngeal carcinoma receiving radiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: The relationship between peripheral blood monocyte count and primary gross tumor volume with survival prognosis in newly diagnosed nasopharyngeal carcinoma(NPC) patients who received radiotherapy remains unclear. Therefore, We conducted a cohort study to assess the association of peripheral blood monocyte count and primary gross tumor volume with survival outcomes in newly diagnosed non-metastatic NPC patients who received radiotherapy. Materials/methods: We included newly diagnosed non-metastatic NPC patients who underwent radiotherapy in our hospital from January 2013 to December 2015. General clinical characteristics such as age, gender, ECOG score and tumor stage, peripheral blood monocyte count, lymphocyte count, white blood cell count (WBC), neutrophil count, radiotherapy technology, total radiotherapy days, gross tumor volume of nasopharyngeal carcinoma (GTVnx) and gross tumor volume of cervix node (GTVnd) of patients before radiotherapy, and whether chemotherapy was induced were recorded. The primary endpoint was overall survival, the secondary endpoint was progression-free survival. Univariate and multivariate COX regression were used to analyze the relationship among peripheral blood monocyte count, GTVnx, and survival outcomes. Spearman correlation analysis was used to analyze the correlation between risk factors. Based on the independent risk factors for OS, we further divide patients into three different risk groups, and the differences in clinical and therapeutic indicators and survival outcomes between the three groups were analyzed using a one-way analysis of variance. Results: A total of 448 participants were included in the study, the median follow-up time was 74.3 months. Of these, 97 (21.7%) died. In the univariate and multivariate Cox regression analyses, peripheral blood monocyte count and GTVnx were independently associated with OS. The high monocyte count and GTVnx were associated with the poor OS and PFS. Correlation analysis showed that monocyte count was positively correlated with WBC, platelet, and neutrophil. GTVnx was positively correlated with platelet, neutrophil, and Epstein-Barr virus before treatment. Survival curves significantly differed among patients in different risk groups for OS (p = 0.0008) and PFS (p = 0.0007). Besides, For every increase in monocyte unit count, the OS and PFS risks of patients in the low GTVnx group increased by 2.64 and 2.31 folds, respectively. Conclusions: Peripheral blood monocyte count combined with GTVnx is an independent predictor for overall survival and progression free-survival in newly diagnosed non-metastatic NPC patients who received radiotherapy. The benefit of patients with GTVnx< 28.5cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.